In 2012, this was the first extramural trial of this technology in the United States outside the NIH. This new clinical approach is helping to lay the foundation for the evaluation of Focal Therapy, which only treats the diseased portion of the prostate. As of May 2016, Dr. Rastinehad was the first in the world to perform a gold nano-particle directed ablation for localized prostate cancer. This was performed using a novel transperineal EM tracked MR US fusion biopsy system that was developed by Dr. Rastinehad and Drs. Pinto, Wood and Choyke from the NIH.
Since medical school, education has always played a pivotal role in Dr. Rastinehad’s ethos. He has been the course director and/or faculty for more than 30 courses nationally and internationally. In 2014, he was the course director for the first MR/US fusion guided biopsy course supported by the AUA. He continues to meet the needs of the AUA members by leading the charge on educating urologists on how to read, segment and target suspicious areas of the prostate with mpMRI and ultrasound.
This past year, Dr. Rastinehad announced the world’s first joint fellowship in ‘Interventional Urology’. Continuing his goal to help bring these new treatments and approaches to the urologic community, he is developing the first Interventional Urology mobile platform combining image fusion, cone-beam CT/fluoroscopy, optical/EM tracking along with ESWL, ultrasound and the newest advances in radiation safety; this will provide a platform for urologists to leverage these technologies and perform interventional treatments in their own operating rooms.
Dr. Rastinehad’s research has been published in leading national and international medical journals. He has published over 75 articles and multiple text book chapters including Urinary Tract Imaging: Basic Principles: Campbells-Walsh Urology 11th and 12th Edition. Dr. Rastinehad is a leader in his field of Uroradiology and was the senior editor of the first comprehensive textbook on the subject, ‘Interventional Urology’, in 2016.
Dr. Rastinehad continues to dedicate his time to caring for patients by researching and developing new diagnostic and therapeutic interventions for urologic diseases, as well as training the next generation of urologists.